<h1>AI companion app beta poses data protection, cross-border transfer, consent, medical-device classification, consumer protection and liability risks (Art. 9 GDPR)</h1> A technology start-up has launched the beta of an AI-driven personal companion app combining chat, journaling, mood tracking and calendar integration, offered worldwide with secure sign-up and chat history. Legal considerations include data protection and cross-border transfer compliance, informed consent and terms for sensitive health-related data, potential regulatory classification as a mental health or medical device in some jurisdictions, consumer protection and misleading-claims risk regarding therapeutic benefits, liability allocation for harms from AI advice, and the need for robust security, transparency and user-feedback governance during beta testing; the release is presented as a press statement.